Envoy Medical Announces the Grant of Its 40th U.S. Patent
Rhea-AI Summary
Envoy Medical (NASDAQ: COCH) announced the grant of its 40th active U.S. patent, U.S. Patent No. 12,485,288, covering cochlear implant stimulation calibration that enables real-time measurement and adjustment of electrical current to the auditory nerve.
The company says this adds to a portfolio that includes 45 issued foreign patents. Envoy notes its Acclaim cochlear implant received Breakthrough Device Designation (FDA, 2019) and is currently under investigation in a U.S. pivotal clinical trial.
Positive
- 40 active U.S. patents
- 45 issued foreign patents
- Patent covers real-time stimulation calibration
- Acclaim retains FDA Breakthrough Device designation
Negative
- Acclaim remains investigational in a U.S. pivotal clinical trial
- No FDA market clearance or commercial approval disclosed
News Market Reaction – COCH
On the day this news was published, COCH declined 0.54%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
COCH was up 3.15% pre-news while key peers like VVOS (-4.95%) and ADGM (-4.58%) were down, indicating stock-specific dynamics rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2025-12-10 | Clinical trial update | Positive | +3.1% | Reported first activations in final stage of pivotal Acclaim study with no SAEs. |
| 2025-12-04 | Investor event | Positive | +4.5% | Announced fireside chat featuring CEO and first Acclaim cochlear implant patient. |
| 2025-12-02 | Patent grant | Positive | -0.5% | Disclosed 40th active U.S. patent for cochlear implant stimulation calibration. |
| 2025-11-20 | Patent grant | Positive | -1.8% | Announced new U.S. patent for implant system with removable earplug sensor. |
| 2025-11-18 | Clinical milestone | Positive | +17.5% | First 10 pivotal trial patients reached six‑month follow-up with no serious events. |
Recent COCH news has been largely positive (IP and clinical updates), with 3 price moves aligning positively and 2 showing negative divergence.
Over the past months, Envoy Medical reported multiple milestones, including six‑month follow-up data for the first 10 Acclaim trial patients with no serious adverse events (Nov 18, 2025) and progress to final-stage activations on Dec 10, 2025. The company has also expanded its IP with several U.S. patents tied to fully implanted cochlear technology. These updates, together with today’s 40th U.S. patent, reflect a consistent focus on advancing the Acclaim pivotal trial and strengthening its technology base.
Market Pulse Summary
This announcement highlights Envoy Medical’s strengthening IP position with its 40th active U.S. patent and 45 foreign patents, focused on fully implanted cochlear technology. It complements the Acclaim implant’s FDA Breakthrough Device Designation (2019) and ongoing pivotal U.S. trial. Recent SEC filings point to going-concern language, Nasdaq listing compliance challenges, and reliance on capital-raising. Investors may watch trial progress, additional patents, and future financing or listing developments as key markers of execution.
Key Terms
cochlear implant medical
intellectual property technical
Breakthrough Device Designation regulatory
pivotal clinical trial medical
auditory nerve medical
AI-generated analysis. Not financial advice.
New Patent Adds to Company's Growing Portfolio of Intellectual Property Focused on Fully Implanted Hearing Devices
White Bear Lake, Minnesota--(Newsfile Corp. - December 2, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received its 40th active U.S. Patent from the United States Patent and Trademark Office. The new patent further strengthens the Company's intellectual property portfolio, which includes an additional 45 issued foreign patents.
U.S. Patent No. 12,485,288, Cochlear Implant Stimulation Calibration, covers proprietary cochlear implant systems designed to enhance performance and reliability. The protected technology enables real time measurement and adjustment of electrical current delivered from the implant's stimulator to the auditory nerve.
"Announcing the grant of our 40th active U.S. patent is an exciting milestone, especially when you consider the additional 45 foreign issued patents we also have," said Brent Lucas, Chief Executive Officer of Envoy Medical. "Imagine where we could be in another couple of years as new patents issue and we expand upon what we already have? We will continue our commitment to the future of hearing devices and look forward to what our team will think of next. While others will need to focus on protecting the past, we look forward to investing in the future."
The Acclaim cochlear implant received Breakthrough Device Designation from the FDA in 2019 and is currently under investigation as part of a U.S. based pivotal clinical trial. For more information on the trial, visit www.envoymedical.com/acclaim-pivotal.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operations; the ability to obtain additional patents and develop future products or product improvements; the ability to obtain and maintain compliance with Nasdaq rules and requirements; the timing and future outcome of its FDA pivotal trial; the ability to raise capital and the amount of capital required to complete the FDA pivotal trial; the Acclaim CI being the first to market fully implanted cochlear implant; the timing and results of activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI; and the participation or any changes or delays in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the timing and results of the Acclaim CI's PMA submission to the FDA; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; the ability to engage competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: Envoy@kcsa.com
Media Contact:
Anne Donohoe
KCSA Strategic Communications
O: 732-620-0033
E: Envoy@kcsa.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276539
FAQ
What patent did Envoy Medical (COCH) receive on December 2, 2025?
How many active U.S. patents does Envoy Medical (COCH) now hold?
What does the new COCH patent protect for the Acclaim cochlear implant?
Does Envoy Medical (COCH) have international patent coverage?
Is the Acclaim cochlear implant approved for commercial use in the U.S.?
Where can investors find details about the Acclaim pivotal trial for COCH?
